Safety of SP-420 in the Treatment of Transfusional Iron Overload

  • STATUS
    Recruiting
  • End date
    Aug 20, 2024
  • participants needed
    28
  • sponsor
    The University of Texas Health Science Center at San Antonio
Updated on 7 October 2022
hysterectomy
oophorectomy
packed red blood cells
serum ferritin level
chelation therapy
chelators
iron chelator

Summary

This study enrolls patients with myelodysplastic syndrome (MDS) and myelofibrosis (MFS), with transfusional iron overload and treats them with the investigational iron chelator, SP-420. SP-420 may be better tolerated and safer than commercially available iron chelators. Iron chelation therapy (ICT) has been shown to improve outcomes in iron overload, but adherence is poor due to problems related to ease of administration, tolerability, and safety.

Details
Condition Iron Overload
Treatment SP-420, SP-420
Clinical Study IdentifierNCT04741542
SponsorThe University of Texas Health Science Center at San Antonio
Last Modified on7 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age ≥18
Diagnosis of MDS or MF with transfusional iron overload
Patients with MDS, will include only those with MDS Revised international prognostic scoring system (IPSS-R) risk group of intermediate, high, or very high
Patients with MF, will include only those with Dynamic International Prognostic Scoring System-Plus (DIPSS=Plus) risk category of intermediate-1, intermediate-2, and high risk
Not appropriate for other iron chelation therapy, per physician
Received 10 or more units of packed red blood cells in the preceding 24 months and remains red cell transfusion dependent
ECOG ≤ 3
ALT ≤ 3 times the upper limit of the normal range
Estimate glomerular filtration rate calculated using Cockroft Gault of ≥ 60 mL/min/1.73m2
Serum ferritin ≥1000 ng/ml
Willing to comply with all study procedures and be available for the duration of the study
Able to take oral medication and be willing to adhere to study medication for 28 days
Female patient must be post-menopausal (no menses for > 12 consecutive months) or surgically sterile (i.e., bilateral oophorectomy, hysterectomy, or tubal sterilization; must agree to completely abstain for heterosexual intercourse; or, if sexually active, must agree to use 1 of the following methods for birth control from the date she signs the consent form until 30 days after final dose of the study drug
Progesterone implant
Intrauterine device
Combination of 2 highly effective birth control methods (e.g., diaphragm/or cervical cap with spermicide plus a condom, hormonal contraception plus a barrier method, partner with vasectomy conducted >60 days before screening visit plus a hormone or barrier method
Male patients must agree to use 1 of the following methods for birth control from the
date he signs the consent form until 30 days after final dose of the study
drug: be surgically sterile by vasectomy conducted > 60 days before screening
visit plus use a barrier method, or, must agree to completely abstain from
heterosexual intercourse, or must agree to use a combination of 2 highly
effective birth control methods (e.g., diaphragm/or cervical cap with
spermicide plus a condom, hormonal contraception plus a barrier method), or
have a post-menopausal partner plus barrier method

Exclusion Criteria

History of kidney disease including the renal Fanconi syndrome
Proteinuria on urine dipstick greater than trace positive
Pregnant, intending to become pregnant during the study, or breastfeeding
Receiving another investigational drug within 30 days or 3 half-lives of the discontinued investigational agent, whichever is greater, of signing consent
History of significant hepatic impairment, defined by Child-Pugh class C
Active hepatitis B or C disease, evidenced by positive viral PCR
Symptomatic heart failure
Receiving active cytotoxic chemotherapy or radiation therapy for a second malignancy (hormonal therapy or topical therapy for squamous cell/basal cell cutaneous tumors are allowed). Treatment of the underlying hematologic malignancy with azacytidine, decitabine, venetoclax, lenalidomide, or ruxolitinib is permitted. Treatment with the supportive care agents luspatercept or erythropoietin agonists is permitted
Concurrent treatment with Exjade/Jadenu (deferasirox), Desferal (deferoxamine), or Ferriprox (deferiprone) are not permitted. Patients are allowed to stop these chelators and participate in this trial 14 days after discontinuation of the other chelator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note